title: High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracyclic imidazoquinoxalines.
abstract: A series of tetracyclic imidazoquinoxaline analogs was developed which constrain the carbonyl group of the partial agonist 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl] - 4,5-dihydroimidazo[1,5-alpha]quinoxaline (2, U-91571) away from the benzene ring. These analogs orient the carbonyl group in the opposite direction of the previously reported full agonist 1-(5- cyclopropyl-1,2,4-oxadiazol-3-yl)-12,12a-dihydroimidazo[1,5- alpha]pyrrolo [2,1-c]quinoxalin-10(11H)-one (3, U-89267). A number of approaches were utilized to form the "bottom" ring of this tetracyclic ring system including intramolecular cyclizations promoted by Lewis acids or base, as well as metal-carbenoid conditions. The size and substitution pattern of the additional ring was widely varied. Analogs within this series had high affinity for the benzodiazepine receptor on the alpha-aminobutyric acid A chloride ion channel complex. From TBPS shift and Cl- current assays, the in vitro efficacy of compounds within this class ranged from antagonists to partial agonists with only 18a identified as a full agonist. Additionally, several analogs were quite potent at antagonizing metrazole-induced seizures indicating possible anticonvulsant or anxiolytic activity. Unlike 3, analogs in this series did not have high affinity for the diazepam insensitive alpha 6 beta 2 delta 2 subtype. These results suggest that either constraining the carbonyl group away from the benzene ring or the greater planarity that results from the additional cyclic structure provides analogs with partial agonist properties and prevents effective interaction with the alpha 6 beta 2 delta 2 subtype.
authors.affiliation: Department of Structural and Medicinal Chemistry, Upjohn Laboratories, Upjohn Company, Kalamazoo, Michigan 49001, USA.
authors.forename: J W
authors.initials: JW
authors.lastname: Mickelson
authors.forename: E J
authors.initials: EJ
authors.lastname: Jacobsen
authors.forename: D B
authors.initials: DB
authors.lastname: Carter
authors.forename: H K
authors.initials: HK
authors.lastname: Im
authors.forename: W B
authors.initials: WB
authors.lastname: Im
authors.forename: P J
authors.initials: PJ
authors.lastname: Schreur
authors.forename: V H
authors.initials: VH
authors.lastname: Sethy
authors.forename: A H
authors.initials: AH
authors.lastname: Tang
authors.forename: J E
authors.initials: JE
authors.lastname: McGee
authors.forename: J D
authors.initials: JD
authors.lastname: Petke
mesh_terms: D000818:Animals; D002460:Cell Line; D006801:Humans; D008024:Ligands; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D013058:Mass Spectrometry; D008564:Membrane Potentials / Q000187:drug effects; D051379:Mice; D008968:Molecular Conformation; D017924:Nucleopolyhedroviruses / Q000235:genetics; D011810:Quinoxalines / Q000138:chemical synthesis* / Q000378:metabolism / Q000627:therapeutic use; D051381:Rats; D011963:Receptors, GABA-A / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D012640:Seizures / Q000188:drug therapy; D013055:Spectrophotometry, Infrared; D018411:Spodoptera; D013329:Structure-Activity Relationship
chemical_list: D008024:Ligands; D011810:Quinoxalines; D011963:Receptors, GABA-A; D011994:Recombinant Proteins